PRO-2000, an antimicrobial gel for the potential prevention of HIV infection

Curr Opin Investig Drugs. 2008 Feb;9(2):189-200.

Abstract

Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. The company is also investigating its potential to prevent the transmission of other sexually transmitted diseases. In February 2005, Indevus launched a pivotal phase III trial for the prevention of HIV infection in women. At that time, further phase III trials in 12,000 African women were scheduled to begin in 2005. A second phase III trial began for the prevention of sexually transmitted infections, including HIV, herpes, Chlamydia and gonorrhea, in Africa in October 2005.

MeSH terms

  • Animals
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Drug Evaluation, Preclinical
  • Female
  • HIV Infections / prevention & control*
  • HIV-1 / drug effects*
  • Humans
  • Naphthalenesulfonates / chemistry
  • Naphthalenesulfonates / pharmacology
  • Naphthalenesulfonates / therapeutic use*
  • Patents as Topic
  • Polymers / chemistry
  • Polymers / pharmacology
  • Polymers / therapeutic use*
  • Structure-Activity Relationship
  • Vaginal Creams, Foams, and Jellies

Substances

  • Anti-HIV Agents
  • Naphthalenesulfonates
  • PRO 2000
  • Polymers
  • Vaginal Creams, Foams, and Jellies